Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.
In the United States, the novel compound duloxetine has been approved for the treatment of major depressive disorder (MDD) and diabetic peripheral neuropathic pain in the adult population. There are currently no published data on the use of duloxetine in children and adolescents. This report describes the successful treatment of 2 adolescent females with chronic pain and co-morbid MDD. Both patients required admission to a tertiary-care pediatric hospital due to the chronicity, severity, and treatment resistance of their pain syndromes. In both cases, duloxetine provided rapid improvement in the experience of pain, as well as mood symptoms, at minimum dosages. Pain symptom reduction and restoration of a euthymic state was maintained at 4- and 3-month follow-up visits, respectively, with minimal to no adverse effects being reported. These cases present preliminary evidence of promising uses for duloxetine in the pediatric population.
Meighen
Karen G
KG
Department of Psychiatry, Section of Child and Adolescent Psychiatry, Indiana University School of Medicine, Indiana, USA. kmeighen@iupui.edu
D015746:Abdominal Pain / Q000188:drug therapy / Q000523:psychology; D000293:Adolescent; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D015897:Comorbidity; D003424:Crohn Disease / Q000188:drug therapy / Q000523:psychology; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy / Q000523:psychology; D010146:Pain / Q000188:drug therapy* / Q000523:psychology; D012803:Sick Role; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride